Ocrelizumab
- Generic Name
- Ocrelizumab
- Brand Names
- Ocrevus
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 637334-45-3
- Unique Ingredient Identifier
- A10SJL62JY
- Background
Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as rituximab, ...
- Indication
用于治疗复发型多发性硬化症（MS）。
- Associated Conditions
- Clinically Isolated Syndrome (CIS), Primary Progressive Multiple Sclerosis (PPMS), Relapsing Multiple Sclerosis (RMS), Relapsing Remitting Multiple Sclerosis (RRMS), Active Secondary Progressive Multiple Sclerosis (SPMS)
- Associated Therapies
- -
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)
- Conditions
- Interventions
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 171
- Registration Number
- NCT05123703
- Locations
- 🇺🇸
UC San Diego; ACTRI, La Jolla, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇧🇷L2 Ip - Instituto de Pesquisas Clinicas Ltda - ME, Brasilia, DF, Brazil
A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab
- Conditions
- Interventions
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT04998851
- Locations
- 🇺🇸
Brigham and Womens Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis, Owosso, Michigan, United States
🇺🇸Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy
- Conditions
- Interventions
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 44
- Registration Number
- NCT04998812
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇫🇷Hôpital de la Pitié Salpétrière, Paris, France
Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial
- Conditions
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Target Recruit Count
- 1
- Registration Number
- NCT04971005
- Locations
- 🇩🇪
Universitätsklinikum Mannheim, Mannheim, Germany
🇩🇪Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.
- Conditions
- Interventions
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Yale University
- Target Recruit Count
- 3
- Registration Number
- NCT04877457
- Locations
- 🇺🇸
Cleveland Clinic Melen Center, Cleveland, Ohio, United States
🇺🇸Yale University, North Haven, Connecticut, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Investigation of the Effect of Ocrelizumab on Peripheral Lymphocyte Immunophenotypes with Suppressive Capacity in MS
- Conditions
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Dr Recai Turkoglu
- Target Recruit Count
- 30
- Registration Number
- NCT04874597
- Locations
- 🇹🇷
Health Sciences University Istanbul Haydarpaşa Numune Training and Research Hospital, Neurology Department, Istanbul, Uskudar, Turkey
Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 122
- Registration Number
- NCT04855617
- Locations
- 🇺🇸
Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, Massachusetts, United States
🇺🇸NYU Langone Health Multiple Sclerosis Comprehensive Care Center (NYULH MSCCC), New York, New York, United States
Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 600
- Registration Number
- NCT04688788
- Locations
- 🇩🇰
Department of Neurology, Herlev Hospital, Herlev, Denmark
🇩🇰Department of Neurology, Aalborg University Hospital, Aalborg, Denmark
🇩🇰Department of Neurology, Aarhus University Hospital, Aarhus, Denmark
Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2022-10-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2
- Registration Number
- NCT04676555
- Locations
- 🇦🇺
Novartis Investigative Site, Parkville, Victoria, Australia
Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy
- Conditions
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- Claudio Gobbi
- Target Recruit Count
- 45
- Registration Number
- NCT04640818
- Locations
- 🇨🇭
Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Lugano, Ticino, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.